Moderna Inc. stock falls after cancer vaccine boost as analysts see downside risk

Moderna Inc. (ISIN US60770K1079) stock closed at USD 154.03 on Nasdaq on September 18, 2026, up 2.56% for the day, while the consensus analyst price target of USD 76.72 now implies about 50.2% downside from this level according to recent data.

Cancer vaccine progress lifts Moderna stock

Moderna Inc. reported positive Phase 3 results for its cancer vaccine program in recent weeks, a development that has helped drive the stock higher over the past month according to Pluang on September 20, 2026. Pluang notes that Moderna shares traded at USD 154.04 in its latest snapshot, down 2.55% on that trading day but described as being up sharply over the past month as investors respond to the Phase 3 cancer vaccine data. For retail investors, this provides a concrete pipeline catalyst behind the recent price strength rather than a purely technical move.

At the same time, the latest aggregate view of Wall Street remains cautious. According to MarketBeat as of September 18, 2026, Moderna carries a consensus rating of Hold based on 24 analysts, with no strong buy recommendations, 7 buy ratings, 12 hold ratings and 5 sell ratings. The same overview shows an average price target of USD 76.72, a high target of USD 180.00 and a low target of USD 18.00, which together translate into a modeled downside of about 50.2% from the USD 154.03 closing price on September 18, 2026. The combination of a strong pipeline signal and a cautious valuation stance is the central tension now shaping Moderna stock.

Recent results and financial profile

On the fundamentals side, Moderna is still in an investment-heavy phase. According to the trailing twelve months figures shown by MarketBeat in its September 18, 2026 overview, Moderna reported a trailing twelve months earnings per share of negative USD 7.99, meaning the company is currently loss-making on that basis. The overview also specifies that the company does not pay a dividend and that its trailing price-earnings ratio is not meaningful because of the negative earnings. For investors, the negative EPS underlines how dependent the long-term story remains on converting pipeline assets like the cancer vaccine program into sustainable revenue streams.

While the most recent detailed quarterly revenue and profit figures are not fully listed in the week’s hits, the MarketBeat profile describes Moderna as a biotechnology company focused on developing messenger RNA, or mRNA, medicines and vaccines across a range of indications, including infectious diseases and oncology. That business model explains the current spending profile: significant R&D and clinical trial investments today in the hope of larger revenue and profit contributions later once products clear regulatory hurdles and commercialization begins. Historical context from earlier periods, such as high revenue during the peak of the Covid-19 vaccine rollout, should therefore be treated as a different phase of the company’s cycle rather than representative of its current fundamentals.

Analyst consensus, ownership trends and key risks

The analyst consensus and recent institutional positioning provide additional context beyond the headline price move. According to MarketBeat on September 20, 2026, data compiled from analyst reports show that Moderna’s average rating remains Hold, with the same consensus price target of USD 76.72 referenced above. The report also mentions institutional activity, such as Baird Financial Group increasing its holdings in Moderna shares, which indicates that even with a cautious valuation view, some institutional investors are willing to add exposure, potentially as a long-term bet on the pipeline.

The downside risk highlighted by the consensus target is substantial. At the September 18, 2026 closing price of USD 154.03 on Nasdaq, the implied downside of about 50.2% to the USD 76.72 target reflects a market assessment that the current valuation already prices in very optimistic outcomes for key programs, including the cancer vaccine. If trial data were to disappoint or if regulatory timelines extended, the stock could move closer to the consensus target, compressing the current premium. Additionally, with trailing twelve months EPS at negative USD 7.99 and no dividend, investors do not have an income cushion and are relying on capital gains tied to successful clinical and commercial execution.

Stock performance, valuation gap and trading data

From a trading and market-data perspective, Moderna’s recent share performance has been volatile but generally positive over the past month as noted by Pluang on September 20, 2026. In that snapshot, the stock was quoted at USD 154.04, representing a 2.55% decline on the trading day referenced but coming after a period of gains driven by the Phase 3 cancer vaccine news. MarketBeat’s September 18, 2026 price table shows a closing level of USD 154.03, a 2.56% daily increase compared with the prior close and a 52-week trading range between USD 22.28 and USD 176.66, with a market capitalization of USD 61.50 billion based on the same price.

That range underlines how far the shares have rebounded from their lows. Using the MarketBeat figures, the USD 154.03 closing price on September 18, 2026 sits more than six times above the 52-week low of USD 22.28 and around 12.8% below the 52-week high of USD 176.66. For investors, the lesson from this spread is twofold. First, Moderna stock has already demonstrated that it can move dramatically in response to changes in sentiment around its pipeline and earnings trajectory. Second, even after the recent rally, the shares are still below their yearly highs, suggesting that the market has not fully committed to the most optimistic scenarios despite the promising cancer vaccine data.

Price level and investor takeaway

As of the last completed trading day referenced in the current data, Moderna Inc. stock closed at USD 154.03 on Nasdaq on September 18, 2026, with a market capitalization of about USD 61.50 billion based on that price and a 52-week range from USD 22.28 to USD 176.66. For investors assessing Moderna stock, the combination of strong pipeline momentum, negative trailing earnings and a consensus target nearly half the current price makes valuation discipline and risk tolerance central to any investment decision.

More news and analyses on Moderna Inc. stock